Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice

BJU International

Volumn 98, Issue 1, 2006, Pages 83-88

  Desgrandchamps, François ^a   Droupy, Stephane ^b   Irani, Jacques ^c   Saussine, Christian ^d   Comenducci, Andrea ^e  

^a SAINT LOUIS HOSPITAL   (France)

^b BICÊTRE HOSPITAL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL CIVIL   (France)

^e GLAXOSMITHKLINE   (France)

Author keywords

5 reductase inhibitor; BII; BPH; Discomfort; Dutasteride; IPSS; Quality of life; Visual analogue scale

Indexed keywords

DUTASTERIDE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EJACULATION DISORDER; GYNECOMASTIA; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MICTURITION; OPEN STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SCORING SYSTEM; SEXUAL DYSFUNCTION; STATISTICAL SIGNIFICANCE; SYMPTOM; VISUAL ANALOG SCALE;

AZASTEROIDS; GASTROINTESTINAL DISEASES; GYNECOMASTIA; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 33745061712     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06241.x     Document Type: Article

References (28)

1. National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). Prostate Enlargement. Benign Prostatic Hyperplasia. NIH publications no. 04-3012, 2004 Available at: http://kidney.niddk.nih.gov/kudiseases/pubs/ prostateenlargement/. Accessed March 2006
2. Lee C Cockett A Cussenot K Griffiths K Isaacs W Schalken JA. Regulation of prostate growth. In Chatelain C Denis L Foo K Khoury S McConnell JD, Proceedings of the Fifth International Consultation on Benign Prostatic Hyperplasia. Plymouth: UK Health Publications Ltd, 2001: 79 106
3. McNeal J. Origin and evolution of benign prostatic enlargement. Invest Urol 1978 15: 340 5
4. Madersbacher S Alivizatos G Nordling J Sanz CR Emberton M de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004 46: 547 54
5. AUA Practice Guidelines Committee. AUA guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003 170: 530 47
6. Clark RV Hermann DJ Cunningham GR Wilson TH Morrill BB Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004 89: 2179 84
7. Roehrborn CG Marks LS Fenter T et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004 63: 709 15
8. Roehrborn CG Boyle P Nickel JC Hoefner K Andriole G ARIA3001 ARIA 3002 and ARIA 3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 60: 434 41
9. Roehrborn CG Lukkarinen O Mark S Siami P Ramsdell J Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005 96: 572 7
10. Vray M Hamelin B Jaillon P Round Table No.2, Giens XX. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs. Therapie 2005 60: 339 49
11. Arocho R McMillan CA Sutton-Wallace P. Construct validation of the USA-Spanish version of the SF-36 health survey in a Cuban-American population with benign prostatic hyperplasia. Qual Life Res 1998 7: 121 6
12. Girman CJ Epstein RS Jacobsen SJ et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994 44: 825 31
13. Agence Nationale d'accreditation et d'Evaluation en Sante (ANAES). Guidelines, Department for diagnosis and treatment of benign prostatic hyperplasia 2003. Available at: http://www.anaes.fr. Accessed March 2006
14. de la Rosette JJ Alivizatos G Madersbacher S et al. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001 40: 256 64
15. Roehrborn CG Bartsch G Kirby R et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001 58: 642 50
16. Barry MJ Williford WO Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995 154: 1770 4
17. Barry MJ Fowler FJ O'Leary MP Bruskewitz RC Holtgrewe HL Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urologic Association. Med Care 1995 33 ( Suppl. 4 AS145 55
18. Hsieh FY. Sample size tables for logistic regression. Stat Med 1989 8: 795 802
19. Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 2001 58 ( Suppl. 6 25 32
20. Debruyne F Koch G Boyle P et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002 41: 497 507
21. McConnell JD Bruskewitz R Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998 338: 557 63
22. Hong SJ Rayford W Valiquette L Emberton M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int 2005 95: 15 9
23. Desgrandchamps F. Importance of individual response in symptom score evaluation. Eur Urol 2001 40 ( Suppl. 3 2 7
24. Roehrborn CG Malice M Cook TJ Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001 58: 210 6
25. O'Leary MP Roehrborn C Andriole G Nickel C Boyle P Hofner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003 92: 262 6
26. Rosen R Altwein J Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003 44: 637 49
27. Calais Da Silva F Marquis P Deschaseaux P Gineste JL Cauquil J Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997 31: 272 80
28. van Moorselaar RJ Hartung R Emberton M et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005 95: 603 8